Cargando…

Dendritic Cells and Programmed Death-1 Blockade: A Joint Venture to Combat Cancer

Two decades of clinical cancer research with dendritic cell (DC)-based vaccination have proved that this type of personalized medicine is safe and has the capacity to improve survival, but monotherapy is unlikely to cure the cancer. Designed to empower the patient’s antitumor immunity, huge research...

Descripción completa

Detalles Bibliográficos
Autores principales:	Versteven, Maarten, Van den Bergh, Johan M. J., Marcq, Elly, Smits, Evelien L. J., Van Tendeloo, Viggo F. I., Hobo, Willemijn, Lion, Eva
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2018
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5863527/ https://www.ncbi.nlm.nih.gov/pubmed/29599770 http://dx.doi.org/10.3389/fimmu.2018.00394

Ejemplares similares

Anti-Tumor Potency of Short-Term Interleukin-15 Dendritic Cells Is Potentiated by In Situ Silencing of Programmed-Death Ligands
por: Versteven, Maarten, et al.
Publicado: (2022)

Interleukin-15 Dendritic Cells Harness NK Cell Cytotoxic Effector Function in a Contact- and IL-15-Dependent Manner
por: Anguille, Sébastien, et al.
Publicado: (2015)

Transpresentation of interleukin-15 by IL-15/IL-15Rα mRNA-engineered human dendritic cells boosts antitumoral natural killer cell activity
por: Van den Bergh, Johan, et al.
Publicado: (2015)

Characterization of Interleukin-15-Transpresenting Dendritic Cells for Clinical Use
por: Van den Bergh, J. M. J., et al.
Publicado: (2017)

Dendritic Cell-Based Immunotherapy of Acute Myeloid Leukemia
por: Van Acker, Heleen H., et al.
Publicado: (2019)

HPV vaccine stimulates cytotoxic activity of killer dendritic cells and natural killer cells against HPV-positive tumour cells
por: Van den Bergh, Johan M J, et al.
Publicado: (2014)

Desirable cytolytic immune effector cell recruitment by interleukin-15 dendritic cells
por: Van Acker, Heleen H., et al.
Publicado: (2017)

Interleukin-15 enhances the proliferation, stimulatory phenotype, and antitumor effector functions of human gamma delta T cells
por: Van Acker, Heleen H., et al.
Publicado: (2016)

Dendritic Cell-Based and Other Vaccination Strategies for Pediatric Cancer
por: de Bruijn, Sévérine, et al.
Publicado: (2019)

In vitro expansion of Wilms’ tumor protein 1 epitope-specific primary T cells from healthy human peripheral blood mononuclear cells
por: van der Heijden, Sanne, et al.
Publicado: (2023)

CD56 Homodimerization and Participation in Anti-Tumor Immune Effector Cell Functioning: A Role for Interleukin-15
por: Van Acker, Heleen H., et al.
Publicado: (2019)

Empowering gamma delta T cells with antitumor immunity by dendritic cell-based immunotherapy
por: Van Acker, Heleen H, et al.
Publicado: (2015)

Recent Advances of Immune Checkpoint Inhibition and Potential for (Combined) TIGIT Blockade as a New Strategy for Malignant Pleural Mesothelioma
por: Rovers, Sophie, et al.
Publicado: (2022)

Interleukin-15-Induced CD56(+) Myeloid Dendritic Cells Combine Potent Tumor Antigen Presentation with Direct Tumoricidal Potential
por: Anguille, Sébastien, et al.
Publicado: (2012)

Poly(I:C) Enhances the Susceptibility of Leukemic Cells to NK Cell Cytotoxicity and Phagocytosis by DC
por: Lion, Eva, et al.
Publicado: (2011)

Correction: Interleukin-15-Induced CD56(+) Myeloid Dendritic Cells Combine Potent Tumor Antigen Presentation with Direct Tumoricidal Potential
por: Anguille, Sébastien, et al.
Publicado: (2014)

Interleukin-15-Cultured Dendritic Cells Enhance Anti-Tumor Gamma Delta T Cell Functions through IL-15 Secretion
por: Van Acker, Heleen H., et al.
Publicado: (2018)

Efficient and Non-genotoxic RNA-Based Engineering of Human T Cells Using Tumor-Specific T Cell Receptors With Minimal TCR Mispairing
por: Campillo-Davo, Diana, et al.
Publicado: (2018)

A versatile T cell-based assay to assess therapeutic antigen-specific PD-1-targeted approaches
por: Versteven, Maarten, et al.
Publicado: (2018)

Ribonucleic Acid Engineering of Dendritic Cells for Therapeutic Vaccination: Ready ‘N Able to Improve Clinical Outcome?
por: Willemen, Yannick, et al.
Publicado: (2020)

The Ins and Outs of Messenger RNA Electroporation for Physical Gene Delivery in Immune Cell-Based Therapy
por: Campillo-Davo, Diana, et al.
Publicado: (2021)

Rapid Assessment of Functional Avidity of Tumor-Specific T Cell Receptors Using an Antigen-Presenting Tumor Cell Line Electroporated with Full-Length Tumor Antigen mRNA
por: Campillo-Davo, Diana, et al.
Publicado: (2020)

The tumor-associated antigen RHAMM (HMMR/CD168) is expressed by monocyte-derived dendritic cells and presented to T cells
por: Willemen, Yannick, et al.
Publicado: (2016)

CD56 in the Immune System: More Than a Marker for Cytotoxicity?
por: Van Acker, Heleen H., et al.
Publicado: (2017)

The Search for an Interesting Partner to Combine with PD-L1 Blockade in Mesothelioma: Focus on TIM-3 and LAG-3
por: Marcq, Elly, et al.
Publicado: (2021)

Finishing touch to joint venture
Publicado: (2003)

Joint venture : los secretos para una administración exitosa
por: Harrigan, Kathryn Rudie
Publicado: (1992)

Interleukin-15 stimulates natural killer cell-mediated killing of both human pancreatic cancer and stellate cells
por: Van Audenaerde, Jonas R.M., et al.
Publicado: (2017)

A joint venture : the economics of constitutional options.
Publicado: (1991)

Joint ventures : y otras formas de cooperación empresaria internacional
Publicado: (1992)

El Joint venture : los negocios jurídicos relacionados /
por: Madrid Andrade, Mario de la
Publicado: (2005)

Joint international business ventures in Mexico
por: Kalmanoff, George
Publicado: (1959)

Alianzas estratégicas o joint ventures /
por: Ginebra Serrabou, Xavier
Publicado: (2000)

Sampling Site Matters When Counting Lymphocyte Subpopulations
por: Ogunjimi, Benson, et al.
Publicado: (2012)

Abundant expression of TIM-3, LAG-3, PD-1 and PD-L1 as immunotherapy checkpoint targets in effusions of mesothelioma patients
por: Marcq, Elly, et al.
Publicado: (2017)

NTRK Fusions in Sarcomas: Diagnostic Challenges and Clinical Aspects
por: Siozopoulou, Vasiliki, et al.
Publicado: (2021)

Joint venture y sociedad : acuerdos de coparticipación empresaria /
por: Le Pera, Sergio
Publicado: (1984)

Short-term cultured, interleukin-15 differentiated dendritic cells have potent immunostimulatory properties
por: Anguille, Sébastien, et al.
Publicado: (2009)

Immune Checkpoint Inhibitory Therapy in Sarcomas: Is There Light at the End of the Tunnel?
por: Siozopoulou, Vasiliki, et al.
Publicado: (2021)

East-West joint ventures : economic, business, financial, and legal aspects.
Publicado: (1988)

Cannot write session to /tmp/vufind_sessions/sess_s4971qm8osidsol673n4b2l5ij